These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

618 related items for PubMed ID: 27138902

  • 1. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
    Shimon I, Sosa E, Mendoza V, Greenman Y, Tirosh A, Espinosa E, Popovic V, Glezer A, Bronstein MD, Mercado M.
    Pituitary; 2016 Aug; 19(4):429-36. PubMed ID: 27138902
    [Abstract] [Full Text] [Related]

  • 2. Giant prolactinomas in men: efficacy of cabergoline treatment.
    Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA, Colosimo C.
    Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
    [Abstract] [Full Text] [Related]

  • 3. Women with prolactinomas presented at the postmenopausal period.
    Shimon I, Bronstein MD, Shapiro J, Tsvetov G, Benbassat C, Barkan A.
    Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
    [Abstract] [Full Text] [Related]

  • 4. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A, Ferone D, Lastoria S, Cerbone G, Di Sarno A, Di Somma C, Lucci R, Lombardi G.
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [Abstract] [Full Text] [Related]

  • 5. Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases.
    De Menis E, Visentin A, Billeci D, Tramontin P, Agostini S, Marton E, Conte N.
    J Endocrinol Invest; 2001 Feb; 24(2):92-7. PubMed ID: 11263478
    [Abstract] [Full Text] [Related]

  • 6. Resistant prolactinomas: a case series of 26 patients.
    Eshkoli T, Fraenkel M, Zaid D, Cohen D, Yoel U, Tsvetov G, Gorshtein A, Goldbart A, Greenman Y, Shimon I.
    Endocrine; 2022 Aug; 77(2):349-356. PubMed ID: 35604631
    [Abstract] [Full Text] [Related]

  • 7. SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS.
    Tirosh A, Benbassat C, Shimon I.
    Endocr Pract; 2015 Nov; 21(11):1240-7. PubMed ID: 26247115
    [Abstract] [Full Text] [Related]

  • 8. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men.
    Shimon I, Benbassat C, Hadani M.
    Eur J Endocrinol; 2007 Feb; 156(2):225-31. PubMed ID: 17287412
    [Abstract] [Full Text] [Related]

  • 9. Clinical, Hormonal, and Neuroradiological Characteristics and Therapeutic Outcomes of Prolactinomas in Children and Adolescents at a Single Center.
    Yang A, Cho SY, Park H, Kim MS, Kong DS, Shin HJ, Jin DK.
    Front Endocrinol (Lausanne); 2020 Feb; 11():527. PubMed ID: 32849307
    [Abstract] [Full Text] [Related]

  • 10. Giant prolactinomas: are they really different from ordinary macroprolactinomas?
    Espinosa E, Sosa E, Mendoza V, Ramírez C, Melgar V, Mercado M.
    Endocrine; 2016 Jun; 52(3):652-9. PubMed ID: 26561015
    [Abstract] [Full Text] [Related]

  • 11. Giant prolactinomas: clinical manifestations and outcomes of 16 Arab cases.
    Almalki MH, Buhary B, Alzahrani S, Alshahrani F, Alsherbeni S, Alhowsawi G, Aljohani N.
    Pituitary; 2015 Jun; 18(3):405-9. PubMed ID: 25062894
    [Abstract] [Full Text] [Related]

  • 12. Giant GH-secreting pituitary adenomas: management of rare and aggressive pituitary tumors.
    Shimon I, Jallad RS, Fleseriu M, Yedinak CG, Greenman Y, Bronstein MD.
    Eur J Endocrinol; 2015 Jun; 172(6):707-13. PubMed ID: 25792375
    [Abstract] [Full Text] [Related]

  • 13. Mixed Pituitary Gangliocytoma and Prolactinoma Resistant to the Cabergoline Treatment.
    Yano S, Hide T, Uekawa K, Honda Y, Mikami Y, Kuratsu JI.
    World Neurosurg; 2016 Nov; 95():620.e17-620.e22. PubMed ID: 27535625
    [Abstract] [Full Text] [Related]

  • 14. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
    Schöfl C, Schöfl-Siegert B, Karstens JH, Bremer M, Lenarz T, Cuarezma JS, Samii M, von zur Mühlen A, Brabant G.
    Pituitary; 2002 Nov; 5(4):261-5. PubMed ID: 14558675
    [Abstract] [Full Text] [Related]

  • 15. Giant Prolactinomas.
    Shimon I.
    Neuroendocrinology; 2019 Nov; 109(1):51-56. PubMed ID: 30404098
    [Abstract] [Full Text] [Related]

  • 16. Primary medical therapy of micro- and macroprolactinomas in men.
    Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A.
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
    [Abstract] [Full Text] [Related]

  • 17. Macroprolactinomas and Nonfunctioning Pituitary Adenomas and Pregnancy Outcomes.
    Lambert K, Rees K, Seed PT, Dhanjal MK, Knight M, McCance DR, Williamson C.
    Obstet Gynecol; 2017 Jan; 129(1):185-194. PubMed ID: 27926659
    [Abstract] [Full Text] [Related]

  • 18. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
    Iyer P, Molitch ME.
    Endocr Pract; 2011 Jan; 17(3):e55-8. PubMed ID: 21324816
    [Abstract] [Full Text] [Related]

  • 19. Hyperprolactinemia diagnosis in elderly men: a cohort of 28 patients over 65 years.
    Shimon I, Hirsch D, Tsvetov G, Robenshtok E, Akirov A, Fraenkel M, Eizenberg Y, Herzberg D, Barzilay-Yoseph L, Livner A, Friedrich I, Manisterski Y, Ishay A, Yoel U, Masri H.
    Endocrine; 2019 Sep; 65(3):656-661. PubMed ID: 31154607
    [Abstract] [Full Text] [Related]

  • 20. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
    Yamada S, Fukuhara N, Horiguchi K, Yamaguchi-Okada M, Nishioka H, Takeshita A, Takeuchi Y, Ito J, Inoshita N.
    J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.